Objective 
Introduction
The regulation of postprandial hyperglycemia is correlated with the risk of microvascular and macrovascular complications (1) . However, medication noncompliance is prevalent among diabetic patients and is associated with adverse clinical outcomes (2) . Hertz et al. reported that the initial treatment using insulin or an α-glucosidase inhibitor (αGI) was a risk factor for early nonpersistence and discontinuation of treatment (3) . We previously reported that administration of αGI after meals improved compliance (4) (5) (6) (7) . One of the reasons for the poor compliance with αGI treatment is the incidence of adverse gastrointestinal effects. The efficacies and adverse gastrointestinal effects of acarbose and voglibose have been previously reported (8, 9) . Although these agents have a similar glucose-lowering effect (9) , the differences in their adverse gastrointestinal effects were unclear. Miglitol is the first pseudomonosaccharide αGI and the drug has been reported to be more effective at reducing the blood glucose levels at 30 and 60 minutes after a meal than voglibose (10) . This can be explained by the fact that unlike acarbose or voglibose, miglitol is partially absorbed from the small intestine (11) 
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Results
One subject discontinued miglitol dosing on day 2 because of severe diarrhea; this subject rated the adverse gastrointestinal effects of miglitol on day 2 and the results were regarded as the subject's response for day 3.
As shown in Fig. 1 
Discussion
The most important finding of the present study was that the subjects' stools tended to be soft in the miglitol group and firm in the acarbose group. The flatus score in the acarbose group was also greater than that in the miglitol group on days 1 and 3.
Acarbose not only inhibits disaccharidase activity, but also the activities of pancreatic and salivary α-amylase. Unabsorbed polysaccharides in the intestine are broken down by enterobacteria and increase intestinal gas production. Therefore, the flatulence and abdominal bloating scores are likely to be higher after acarbose administration than after miglitol administration. In contrast, miglitol does not inhibit α-amylase (12) . Therefore, the administration of miglitol increases unabsorbed disaccharides, rather than polysaccharides, in the intestine. Disaccharides are known to induce osmotic diarrhea or softening stools (13 Fig. 1 .
In conclusion, because stools tend to be soft when miglitol is administered and firm when acarbose is administered, the condition of the patient's stools and gastrointestinal symptoms may be considered when starting αGI therapy.
